Pharmaceuticals

Drug Development Drug Pricing Drug Safety Drug Approval Weight Loss Drugs Clinical Trials Prescription Drugs Drug Manufacturing Biotechnology Drug Regulation

Soleno Faces Securities Class Action Over DCCR Safety as Investors Weigh May 5 Lead‑Plaintiff Deadline

Investors now confront a court test of claims that Soleno hid safety risks tied to its Prader‑Willi drug and overstated its launch outlook.

Stories older than 24h

Cyclerion to Merge With Korsana in Reverse Takeover Backed by $380 Million

FDA Warns ImmunityBio Over Anktiva Ads as Company Adds $100 Million for Expansion

Ariel Focus Fund Details Mixed Q4, Oracle AI Push and Barrick Payouts in New Letter

Takeda Confirms Nearly 250 Cambridge Layoffs Under Cost-Saving Plan

Law Firms Seek Ultragenyx Investors to Lead Securities Class Actions After OI Trial Miss

GSK Gains After Cramer Endorsement as Company Pushes Into Weight-Loss Drugs

ADMA Biologics Denies Short-Seller Report as Shares Rebound and Law Firms Launch Probes

Soleno Hit With Securities Class Action Over Prader‑Willi Drug DCCR

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

CVS, FTC Reach Proposed Settlement Over Insulin Pricing

DeSantis Signs $31 Million Stopgap To Restore Florida ADAP Access Through June

AbbVie and Bristol Myers Defy Their Sector With Rising Dividends Fueled by New Drugs

Eton Pharma Launches FDA-Approved Desmota as Revenue and Margins Jump

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

HSBC Cuts Eli Lilly to Reduce, Lowers Target to $850 on GLP-1 Reset

Eli Lilly’s Tirzepatide Surge Collides With Rich-Valuation Concerns

Zevra Sells SDX Portfolio to Commave for $50 Million, Settles Delaware Suit

Biomea Fusion Reports Positive 52-Week Phase II Results for Icovamenib in Diabetes

Report Says Complications Rose After FDA Allowed Mail-Order Abortion Pills